ICER says AstraZeneca's Baxfendy ($10,950/yr) and Mineralys' lorundrostat don't justify costs vs. generic hypertension drugs like spironolactone and amiloride.
The drug price watchdog ICER issued a report Thursday concluding that the benefits of AstraZeneca’s new blood pressure pill Baxfendy don’t justify its $10,950 per …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that…
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…
AstraZeneca announced the FDA approved baxdrostat for uncontrolled hypertension as add-on therapy on top of standard…
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the…
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA,…
Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives
